Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Episurf Medical AB (publ)    EPIS B   SE0003491562

EPISURF MEDICAL AB (PUBL)

(EPIS B)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Episurf Medical : Results from Swedish multi-centre clinical trial with follow-up of 30 Episealer® patients accepted for scientific publication

09/30/2020 | 02:31am EST

Episurf Medical (Nasdaq: EPIS B) today announces that results from a clinical study with follow-up of the 30 first Episealer® patients from nine Swedish clinics has been accepted for publication in the scientific journal Cartilage. The publication is expected to be available online shortly. The study reports on good implant safety and significantly improved patient-reported outcome scores. In total, 30 patients are included in the study and the average follow-up time is 55 months (subjective outcome scores at 24 months, survival data at 24 - 86 months, mean of 55 months).

The Episealer® Knee implant is intended for treatment of focal cartilage and osteochondral defects on the femoral side of the knee joint. These defects often imply severe pain, which significantly can impact the patient's quality of life. Current standard of care, which includes various biological treatment alternatives, has shown limited effectiveness, especially with increasing age.

The study is a prospective consecutive cohort study, with the objective to assess subjective short-term outcome and possible longer-term risks of the Episealer® intervention. The study results are compiled by principle investigator MD PhD A. Stålman at Capio Artro Clinic, Stockholm. The patients in the study received an Episealer® Knee implant during the years 2012 - 2017. Of the 30 patients, one patient has undergone revision to a partial knee prosthesis. The patient-reported outcome scores EQ5D VAS (EuroQoL Visual Analogue Scale), VAS-pain (Visual Analogue Scale) and KOOS (Knee injuries and Osteoarthritis Outcome Score) all show significant improvements.

"Again, we note that the satisfactory clinical results previously reported are corroborated, now in a new Swedish study. Further, the risk of revision is again shown to be low. It all points to the Episealer® being a reliable and effective mode of treatment for these "GAP-patients" (being too old for biological cell treatment and too young for a knee prosthesis)" says Prof. Leif Ryd, Senior medical advisor of Episurf Medical.

 

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
 

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical's Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical's μiFidelity® system enables implants to be cost-efficiently tailored to each individual's unique injury for the optimal fit and minimal intervention. Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company's website: www.episurf.com.

This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CEST on 30 September 2020.

https://news.cision.com/episurf/r/results-from-swedish-multi-centre-clinical-trial-with-follow-up-of-30-episealer--patients-accepted-f,c3205288

https://mb.cision.com/Main/14691/3205288/1312633.pdf

(c) 2020 Cision. All rights reserved., source Press Releases - English

All news about EPISURF MEDICAL AB (PUBL)
11/30EPISURF MEDICAL : Episealer® presentation at the Combined Bristol & Oxford Unico..
AQ
11/27EPISURF MEDICAL : enters into international advisory agreement
AQ
11/26EPISURF MEDICAL : carries out a directed share issue and raises proceeds of SEK ..
AQ
11/13EPISURF MEDICAL : First Episealer® surgery in Scotland performed
AQ
11/04EPISURF MEDICAL : First Episealer® Talus surgery in Scandinavia performed
AQ
10/26DNB MARKETS - EPISURF MEDICAL :  Clinical data strengthens the case
AQ
10/26EPISURF MEDICAL : First Episealer® surgery performed in Asia
AQ
10/23EPISURF MEDICAL : Interim Report 1 July - 30 September 2020
AQ
10/15EPISURF MEDICAL : enters into a distribution agreement for additional markets in..
AQ
10/14EPISURF MEDICAL : Members of the Nomination Committee for Episurf Medical's Annu..
AQ
More news
Financials
Sales 2020 6,00 M 0,71 M 0,71 M
Net income 2020 -72,8 M -8,62 M -8,62 M
Net cash 2020 81,0 M 9,59 M 9,59 M
P/E ratio 2020 -5,67x
Yield 2020 -
Capitalization 419 M 49,6 M 49,6 M
EV / Sales 2020 56,4x
EV / Sales 2021 35,2x
Nbr of Employees 25
Free-Float 89,1%
Chart EPISURF MEDICAL AB (PUBL)
Duration : Period :
Episurf Medical AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EPISURF MEDICAL AB (PUBL)
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts 2
Average target price 4,00 SEK
Last Close Price 2,27 SEK
Spread / Highest target 76,6%
Spread / Average Target 76,6%
Spread / Lowest Target 76,6%
EPS Revisions
Managers
NameTitle
Pål Ryfors Chief Executive Officer
Dennis D. Stripe Chairman
Katarina Flodstrom Chief Operating & Regulatory Officer
Veronica Wallin Chief Financial Officer
Leif Erik Sigfrid Ryd Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
EPISURF MEDICAL AB (PUBL)97.01%50
STRYKER CORPORATION11.58%88 033
SMITH & NEPHEW PLC-18.14%17 516
INSPIRE MEDICAL SYSTEMS, INC.158.05%5 158
VENUS MEDTECH (HANGZHOU) INC.99.33%4 016
GLAUKOS CORPORATION27.67%3 125